Patents by Inventor Mark Appleby

Mark Appleby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-17C ANTAGONISTS AND METHODS OF USING THE SAME
    Publication number: 20070129302
    Abstract: The present invention relates IL-17RE antagonists, such as soluble receptors and anti-IL-17RE antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. IL-17RE is a receptor for IL-17C. The present invention includes soluble IL-17RE, anti-IL-17RE antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: October 18, 2006
    Publication date: June 7, 2007
    Inventors: Zeren Gao, Rolf Kuestner, Mark Appleby, Katherine Lewis, Patricia McKernan, Shannon Okada, David Taft, Joseph Kuijper, Stephen Jaspers, Steven Levin
  • SOLUBLE ZCYTOR21, ANTI-ZCYTOR21 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20070049525
    Abstract: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: October 4, 2006
    Publication date: March 1, 2007
    Inventors: Zeren Gao, Rolf Kuestner, Mark Appleby, Katherine Lewis, Patricia McKernan, Shannon Okada, David Taft, Joseph Kuijper, Stephen Jaspers, Steven Levin
  • SOLUBLE ZCYTOR21, ANTI-ZCYTOR21 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20070049524
    Abstract: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: October 4, 2006
    Publication date: March 1, 2007
    Inventors: Zeren Gao, Rolf Kuestner, Mark Appleby, Katherine Lewis, Patricia McKernan, Shannon Okada, David Taft, Joseph Kuijper, Stephen Jaspers, Steven Levin
  • Soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners and methods of using in inflammation
    Publication number: 20060142192
    Abstract: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: October 18, 2005
    Publication date: June 29, 2006
    Inventors: Zeren Gao, Rolf Kuestner, Mark Appleby, Katherine Lewis, Patricia McKernan, Shannon Okada, David Taft, Joseph Kuijper, Stephen Jaspers, Steven Levin
  • Manipulation of cytokine levels using cd83 gene products
    Publication number: 20060083740
    Abstract: The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.
    Type: Application
    Filed: November 21, 2002
    Publication date: April 20, 2006
    Applicant: Celltech R&D, Inc.
    Inventors: Fred Ramsdell, Sean Proll, Karen Staehling-Hampton, Mark Appleby, Leon Garcia-Martinez
  • Ztnf13, a tumor necrosis factor
    Publication number: 20050250126
    Abstract: Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
    Type: Application
    Filed: December 16, 2004
    Publication date: November 10, 2005
    Inventors: Zeren Gao, Paul Sheppard, Brian Fox, James Holloway, Stephen Jaspers, Mark Appleby